Inno-206
Cardiotoxicity
Beth Israel Deaconess Medical CenterPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
13 Active assets in the Cardiotoxicity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
POTASSIUM Tufts Medical Center | Phase 3 | BB |
Orlistat University of British Columbia | Phase 4 | BB |
CARVEDILOL Abramson Cancer Center at Penn Medicine | Phase 3 | BB |
WARFARIN Massachusetts General Hospital | Phase 3 | BB |
Calcium | Phase 3 | BB |
View all 36 →
Same molecule, other indications
Inno-206 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →